We're ScreenPoint Medical

We are focused on helping to improve breast cancer survival rates by detecting cancers earlier so that treatment can be more effective and less invasive.

Improve patient outcomes

We are working with breast clinicians to continually improve the clinically proven deep learning algorithms in Transpara™. We are committed to further improve accuracy, consistency and reduce unnecessary recalls, a common cause of anxiety for women undergoing mammography.

Deep learning
From the leaders in development of deep learning Artificial Intelligence (AI) for mammography and breast imaging picture

40 years experience

From the leaders in development of deep learning Artificial Intelligence (AI) for mammography and breast imaging

Our history

ScreenPoint Medical was founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, world leading experts in quantitative breast image analysis and computer aided detection.

Read more

Our history

ScreenPoint Medical was founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, world leading experts in quantitative breast image analysis and computer aided detection.

They have led research projects in the field for over twenty years and have made important contributions to leading breast imaging products. 

Prof Karssemeijer says, “I started ScreenPoint Medical because I wanted my academic work to have a greater impact beyond the publication of scientific papers. I knew our work held out the promise to ultimately improve breast cancer survival rates and recognised the huge potential of my university team to develop a really outstanding product. By using the technological advances of Deep Learning Artificial Intelligence, we have overtaken current CAD systems to produce faster and more accurate results.”



Our technology

The resulting product, Transpara, has featured in multiple peer-reviewed publications that show it enables significant clinical improvements to the timely diagnosis of breast cancer.

Read more

Our technology

The resulting product, Transpara, has featured in multiple peer-reviewed publications that show it enables significant clinical improvements to the timely diagnosis of breast cancer.

“Transpara is now being used by radiologists in clinical practice, but this is only the beginning! We are constantly innovating and we will continue to help doctors to achieve higher breast cancer survival rates and at the same time, minimise patient distress and the cost of unnecessary treatments.”

“But we always remember that our excellence in innovation must be matched by the way we run our business. We are lean, focused on producing optimum results with cost savings passed on to our customers.”

Co-Founder of ScreenPoint Medical, Sir Michael Brady, was known internationally for his ground-breaking work in robotic image analysis at the University of Oxford but the death of his mother in law from breast cancer, caused him to change direction:

“I wanted to understand why the medical profession wasn’t able to do a better job of detecting breast cancers at an earlier stage when they were more treatable.  So I decided to move away from robotics and concentrate on the analysis of breast scans.’

My colleagues and I developed a mathematical model of the passage of X-rays through female breast tissue, a fundamental step towards developing a system able to recognise potential tumours.

I met Nico Karssemeijer from Nijmegen University in 2000 when he was giving a keynote lecture on parallel research.

Both of us wanted to help radiologists identify potential cancers faster and at an earlier stage and to increase the chances of more women surviving breast cancer.

In 2014 we started ScreenPoint Medical.  We built a superb team of scientists to develop a unique system, Transpara, a blend of classic physics and deep learning artificial intelligence, presented as a decision support tool to increase efficiency.

There are fewer and fewer radiologists specialising in reading mammograms at a time when breast cancer incidence is increasing worldwide.

ScreenPoint are the only people that combine deep understanding of the physics, knowledge of clinical workflow and deep learning AI techniques to improve accuracy and speed of detection. Transpara is the world leader!”



Our team

The Board Members and Executive Team

 picture

Nico  Karssemeijer

CEO

View Biog
 picture

Sir Michael  Brady

Chairman

View Biog
 picture

Carl  Evertsz

Non-Executive Director

View Biog
 picture

Guido  Du Pree

Non-Executive Director

View Biog
 picture

Anirudha  Dambal

Non-Executive Director

View Biog
 picture

Pieter  Kroese

COO

View Biog
 picture

Albert  Gubern-Mérida

CTO

View Biog

Research & Development and Clinical

 picture

Elisabeth  Elbers

Data Manager

View Biog
 picture

Jaap  Kroes

Lead Research Team

View Biog
 picture

Gertjan  Laarakkers

Software Engineer

View Biog
 picture

Alejandro  Rodriguez-Ruiz

Research Scientist

View Biog
 picture

Natasja  Janssen

Clinical Scientist

View Biog
 picture

Suzanne  Van den Elsen

Research Scientist

View Biog
 picture

Esther   Smits

Clinical Application Specialist

View Biog
 picture

Freeke  Porte

Clinical Application Specialist

View Biog
 picture

Henny  Rijken

Medical Education Manager

View Biog

Commercial Team

 picture

Nicki  Bryan

VP of Sales USA

View Biog
 picture

Gina   Dailey

Transpara Customer Success & SE Sales Director USA

View Biog
 picture

Len  Kosloski

Technical & Western Sales Director USA

View Biog
 picture

Marvin  Fok

Head of Sales Distribution

View Biog
 picture

Jerney  Hensen-Tirtosentono

Office Manager

View Biog

Finance, HR and RA

 picture

Joost  Van Wamel

Business Controller

View Biog
 picture

Marieke  de Blois

HR Manager

View Biog
 picture

Umar  Waqas

Head of Regulatory and Quality Affairs

View Biog
 picture

Joost  Van Rijn

QA and RA Officer

View Biog
 picture

Nico Karssemeijer

CEO

Professor Nico Karssemeijer is a leading scientist in breast cancer imaging and has been one of the pioneers of computer-aided detection, playing a key role in its development and adoptation in breast cancer screening. He was closely involved in the development of the R2 ImageChecker, the first mammography CAD product. He also played an important role in implementing digital mammography in the European screening programs, by initiating and leading EU funded projects in which breast screening workstations were developed that are marketed today by major vendors. He is a Professor in the Department of Radiology, Radboud University, Nijmegen, The Netherlands, and he is co-founder of Matakina Ltd and of QView Medical Inc.

 picture

Sir Michael Brady

Chairman

Professor Sir Michael Brady FRS FMedSci FREng is a world leading scientist in computer vision, robotics, and medical image analysis.  He co-authored Mammographic Image Analysis (Kluwer 1999) with Ralph Highnam; the ideas introduced in this monograph – together with some later innovative developments by Nico Karssemeijer and colleagues – provided the basis for Volpara density.  As well, Brady has co-founded and steered several small high-growth technology companies to success.  In addition to Matakina, he is a Founder Director of: Perspectum Diagnostics, Mirada Medical, and Guidance Navigation; as well as being Chairman of:  Acuitas Medical, IRISS Medical, Colwiz,  and was until recently Deputy Chairman of Oxford Instruments plc.

 picture

Carl Evertsz

Non-Executive Director

Dr. Carl Evertsz has extensive experience founding, leading, and growing innovative medical imaging companies. He actively led international business-, corporate- and R&D- developments, including an IPO, M&A and technology acquisitions. He also spearheaded the development and commercialization of multi-modality breast reading solutions, which significantly contributed to creating today’s de facto industry standards. Until 2012 Carl served as CEO of MeVis Medical Solutions AG, a publicly traded developer and provider of medical imaging software that he co-founded, and of MeVis BreastCare. He is managing director and owner of Pandushi, a private asset management and investment firm and serves in the supervisory board of Medis Medical Imaging Systems B.V.

 picture

Guido Du Pree

Non-Executive Director

Guido du Pree, M.Sc. has many years of experience in venturing, (digital) innovation and revenue growth in Medical Imaging, IVD, Healthcare Informatics and Genomics companies. He co-founded, built and managed the Philips Digital Pathology venture. Currently the venture is one of the spearheads in Philips Health growth ambitions with tens of millions of revenue and more than 300 people on the payroll. Two years ago, Guido founded an online market place for innovative Molecular/Genetic Diagnostic tests to make these tests easy available to cancer patients and their doctors. The first part of his career he spent in strategy consulting, M&A and fund raising for start-ups.

 picture

Anirudha Dambal

Non-Executive Director

Anirudha has strong cross-functional expertise across general management, strategy, product & innovation management, and sales operations addressing customers across the world. In his function as vice president of New X-ray Markets at Siemens Healthineers, he is responsible for identifying and bringing new business opportunities in the X-ray products business line to the market. In his previous role, he was the head of the global value segment X-ray products where he drove the definition and development of a new mobile C-arm platform. He has also served as the head of CRM and sales analytics and as business manager for South Asia in prior positions. As a non-executive director at ScreenPoint Medical, he is jointly working towards improved breast cancer diagnosis using artificial intelligence.

 picture

Pieter Kroese

COO

Pieter Kroese has extensive international experience in general, commercial and financial management, and has always been intensively involved in strategy development. He has a background in various industries, leading organisations of up to 400 people. He also developed hands-on entrepreneurial experience as co-founder of a technical startup company. During the last 7 years, Pieter has primarily been working with software development companies. He joined ScreenPoint in 2018 and is responsible for all business activities, driving the commercial focus and growth of the company, as well as assuming responsibility for operations and finance.

 picture

Albert Gubern-Mérida

CTO

Dr. Gubern-Mérida obtained his joint Ph.D. degree in the field of medical imaging at the Diagnostic Image Analysis Group (DIAG) of the Radboud University Medical Center (Nijmegen, the Netherlands) and the University of Girona (Girona, Spain). His research focused on automated analysis of breast MRI, by developing image analysis and machine learning algorithms for breast cancer detection. As a post-doctoral researcher at DIAG, he expanded his research interest to other breast imaging modalities (mammography, digital breast tomosynthesis, and automated 3D breast ultrasound). In 2016, Dr. Gubern-Mérida joined ScreenPoint Medical, where he is currently the Head of Research and Development, leading the continuous evolution of the AI technology within the company.

 picture

Elisabeth Elbers

Data Manager

 picture

Jaap Kroes

Lead Research Team

 picture

Gertjan Laarakkers

Software Engineer

 picture

Alejandro Rodriguez-Ruiz

Research Scientist

 picture

Natasja Janssen

Clinical Scientist

 picture

Suzanne Van den Elsen

Research Scientist

 picture

Esther Smits

Clinical Application Specialist

 picture

Freeke Porte

Clinical Application Specialist

 picture

Henny Rijken

Medical Education Manager

 picture

Nicki Bryan

VP of Sales USA

 picture

Gina Dailey

Transpara Customer Success & SE Sales Director USA

 picture

Len Kosloski

Technical & Western Sales Director USA

 picture

Marvin Fok

Head of Sales Distribution

 picture

Jerney Hensen-Tirtosentono

Office Manager

 picture

Joost Van Wamel

Business Controller

 picture

Marieke de Blois

HR Manager

 picture

Umar Waqas

Head of Regulatory and Quality Affairs

 picture

Joost Van Rijn

QA and RA Officer

Join our team

ScreenPoint Medical is a fast growing company that develops and markets AI products and services to improve early detection of breast cancer. We always welcome applications from strong candidates who share our mission and have expertise in our field. Feel free to send your resume and motivation letter to us.


Clinical Scientist

Job profile Responsibilities will include: • Initiate and support clinical studies with ScreenPoint products • Develop and maintain relations with


Clinical Application Specialist

Job description ScreenPoint is looking for a highly organized and efficient professional to support the Customer Operations team with installation


Junior Linux Systems Administrator

Job Description ScreenPoint is looking for an enthusiastic and highly skilled Junior Linux Systems Administrator. In this position, you will


Our Partners

We are proud to work with some of the world’s leading organizations.

Transpara is a multi vendor solution and is compatible with most 2D and 3D mammography and PACS vendors.

News

Publication


Major peer reviewed publication in Radiology demonstrates significant workload reduction in BOTH 2D and 3D

Read about how Transpara helps reduce radiologist’s workload by up to 70% for BOTH 2D and 3D mammography in this

Read more

Article


Interested in research with breast AI?

Natasja Janssen, Clinical Scientist ScreenPoint Medical has a clear and compelling mission to help radiologists detect breast cancer as early

Read more

Article


AI breast cancer diagnoses may reduce disparity in women’s mortality

Here’s an interesting article from the Dutch Ministry of Foreign Affairs entitled “AI breast cancer diagnoses may reduce disparity in

Read more

Article


How AI “will out-perform humans” in the fight against breast cancer and other diseases

Professor Nico Karssemeijer and Professor Sir Michael Brady formed ScreenPoint Medical seven years ago with the aim of reducing the

Read more

Announcement


ScreenPoint Medical’s Transpara powered by Fusion AI™ platform sets the new benchmark for breast AI.

ScreenPoint Medical BV, Europe’s leading developer of AI systems for breast care has announced the introduction of Transpara powered by

Read more

Clinical evidence


New publication European Radiology – Can artificial intelligence reduce the interval cancer rate in mammography screening?

A new retrospective study from Sweden published in European Radiology https://doi.org/10.1007/s00330-021-07686-3 showed that Transpara AI detected 19% of interval cancer

Read more